A Phase 1 interventional study of Fexuprazan Injection and Fexuprazan Injection placebo in Erosive Gastroesophageal Reflux Disease, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy participants
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
This study's planned enrollment of 40 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV injection of test drugs by dose group
Drug: Fexuprazan Injection
IV injection of test drugs by dose group
Drug: Fexuprazan Injection placebo
All Participants take IV injection of test drugs
Drug: Fexuprazan Injection_part 2
In the case of test group, take IV injection in the period 1 and take a tablet in the period 2
Drug: Fexuprazan Injection_part 3 · Drug: Fexuprazan tablet
In the case of reference group, take a tablet in the period 1 and take IV injection in the period 2
Drug: Fexuprazan Injection_part 3 · Drug: Fexuprazan tablet
20/40/80 mg
20/40/80 mg
20mg
40mg
40mg
PK of Fexuprazan
1\. Blood and urinary concentrations of Fexuprazan by part
Time frame: 0 and 72hour
PK of metabolite
1\. Blood and urinary concentrations of metabolite by part
Time frame: 0 and 72hour
PD of Fexuprazan
pH monitoring
Time frame: up to 15days
No study locations are listed for this record.
Start is estimated for Jul 2024; primary completion for Jan 2025, 6 months later.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 6 months is above that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →